CASTLE BIOSCIENCES INC CSTL

About CASTLE BIOSCIENCES INC (CSTL): stock profile, AI score and financials

CASTLE BIOSCIENCES INC (CSTL) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CSTL at 39.5/100 on a composite quality score built from its SEC filings, placing it at rank #2,138 of 2,925 stocks — the bottom half of the AI-ranked universe. CSTL scores in the top quartile across earnings quality (85.5). Areas of concern include institutional flow (13.5) and profitability (23.4), which score below median versus the broader universe. Shareholder dilution risk is elevated at 12.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), CASTLE BIOSCIENCES INC reports quarterly revenue of $103.5M, net income of $-2.1M, an operating margin of -3.0%. Top institutional holders of CSTL by reported 13-F value include BlackRock, RTW INVESTMENTS, PRINCIPAL FINANCIAL GROUP, based on the most recent SEC filings. CSTL trades on the Nasdaq exchange and files with the SEC under CIK 1447362. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CSTL daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for CASTLE BIOSCIENCES INC directly from SEC EDGAR.

Financials through the period ended Jun 30, 2026SEC EDGAR: CIK 1447362 →